×
0 0 0.00625000000000009 0.00625000000000009 -0.0125 -0.00624999999999998 -0.0375 -0.03125
Stockreport

Trillium Therapeutics' TTI-621 an Orphan Drug in U.S. for T-cell lymphoma; shares ahead [Seeking Alpha]

Trillium Therapeutics, Inc (TRIL)  More Company Research Source: Seeking Alpha
Last trillium therapeutics, inc earnings: 5/11 07:00 am Check Earnings Report
PDF Trillium Therapeutics' TTI-621 an Orphan Drug in U.S. for T-cell lymphoma; shares aheadTrillium Therapeutics (NASDAQ:TRIL) is up6% premarket on light volume in response to itsannouncement that the FDA has designated TTI-621 an Orphan Drug for the treatment of cutaneous T-cell lymphoma.Phase 1-stageTTI-621 is a fusion protein that activates the innate immune system by blocking the activity of a protein found on the surface of cancer cells called CD47 which allows them to avoid detection by immune cells.Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.See all stocks on the move »Now read:KemPharm reports "positive" results from PK study of ADHD candidate KP415 » [Read more]

IMPACT SNAPSHOT EVENT TIME: TRIL
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
TRIL alerts
from News Quantified
Opt-in for
TRIL alerts

from News Quantified
Opt-in for
TRIL alerts

from News Quantified